It seems to be a recurring problem, though. As you can see from the link above, Science's team found that several of these clinical centers have previously fouled up trial data for other companies and other drugs, and that alone should make any responsible CRO avoid them like radioactive waste zones. But the problems are even deeper. It appears that many of these Miami-area centers are cheerfully enrolling "professional patients" who are signing up for as many trials as possible to collect the payments and benefits, and who are likely as not throwing the pills themselves away. By this point in the article, my head was in my hands, and I'm sure that's a common reaction. This sort of idiotic fraud is the exact opposite of medical research.
Remember the TOPCAT story of what happened in Russia and Georgia?
This is worse: www.science.org/content/blog...
And in South Florida.
From @dereklowe.bsky.social
12.01.2026 19:12 — 👍 18 🔁 10 💬 1 📌 0
A Man with Asymptomatic Hypertension
Sarah Gorey, M.B.
You are the intern on call for the night shift. You are paged to come to the surgical ward to assess a patient. A 63-year-old man with uncomplicated diverticulitis was admitted earlier in the day for antimicrobial and conservative treatment. He rarely visits his family doctor, is not aware of having high blood pressure, and does not take regular medications. You have been called because on a routine check of vital signs, the patient’s blood pressure was 185/115 mm Hg. All other vital signs were within normal limits. The patient has no symptoms; he has no headache, dyspnea, or chest or abdominal pain. He reports feeling slightly stressed at being admitted to the hospital today, which he was not anticipating, but had been sleeping comfortably before the nurse checked his vital signs.
On examination, he appears to be comfortable, and there is no clinical evidence of withdrawal from alcohol or other substances. His abdomen is soft and nontender, and on auscultation, no bruits are heard over the aorta or renal arteries. His pulses are 2+ and symmetric in all anatomical distributions. You note that his blood pressure was also high (166/97 mm Hg) at admission 4 hours earlier and had not been measured again until now. Routine laboratory test results from blood samples obtained at the time of admission show increased levels of leukocytes and inflammatory markers but normal kidney and liver profiles. The nurse manager confirms that the blood-pressure monitors on this ward have been calibrated recently. A repeat blood-pressure measurement obtained after the patient has rested quietly for 10 minutes is still elevated, at 182/103 mm Hg.
You must decide whether the patient’s blood pressure should be monitored over time on an outpatient basis (a “watchful waiting” approach) or whether he should begin receiving antihypertensive medications during this hospitalization.
Should we be treating inpatient hypertension?
Interesting case with two discussants (Michael Rothberg vs Tara Chang)
www.nejm.org/doi/full/10....
I have to confess despite being a nihilist for treating inpatient BP I am tempted to do something in this setting.
09.01.2026 13:52 — 👍 11 🔁 4 💬 1 📌 0
our dietitian mentioned that the oil of the control group is proinflammatory which might explain the difference
what do you and @freelyfiltered.bsky.social think? 🙏
15.12.2025 09:28 — 👍 0 🔁 0 💬 1 📌 0
so whats the fup study?
-> repeat in >70a old immunosuppressed patients?
total n=1000
12.12.2025 14:22 — 👍 0 🔁 0 💬 0 📌 0
no screening in Austria 🇦🇹 😥
28.11.2025 12:08 — 👍 1 🔁 0 💬 0 📌 0
Immune Monitoring Goes Viral 🦠 Torque Teno Virus
for Immunologic Risk Stratification After Kidney Transplantation
⏩️ new review in TI 🔥
doi.org/10.3389/ti.2...
#ttvguide
14.11.2025 07:15 — 👍 4 🔁 2 💬 0 📌 0
American Society of Nephrology Kidney Week 2025
Original Article | Nov. 6, 2025 | NEJM.org
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
Figure 2A. Change from Baseline in 24-Hr Urinary Protein-to-Creatinine Ratio through Week 36.
The NEJM identity sits at the bottom.
ORIGIN phase 3 trial: In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria. nej.md/3JEq8QL
@asnkidney.bsky.social | #KidneyWk
06.11.2025 14:55 — 👍 18 🔁 10 💬 0 📌 0
Figure 2. Change in bodyweight
(A) Mean percent change in bodyweight from baseline to week 48, shown as observed means and bars indicating SEs. The model-based estimates of the mean percent change in bodyweight and differences among treatment groups at week 48 with the corresponding p values (efficacy estimand only) and 95% CIs are shown in (B) (efficacy estimand) and (D) (treatment-regimen estimand); bars indicate SEs. Multiplicity adjustment was not performed, and p values should be interpreted as exploratory. (C) shows the percentage of participants with bodyweight reductions of at least 5%, 10%, 15%, 20%, 25%, and 30% from baseline to week 48. The percentage of participants is annotated above each bar, calculated with the use of Rubin's rules by combining the percentages of participants who met the thresholds in imputed datasets. *The model-based estimates and 95% CIs from a mixed model repeated measures analysis for the efficacy estimand are shown on the right, denoted by 48.
Eli Lilly continuing to hit it out the park
Selective amylin agonist as an alternative to GLP1RAs? #eloralintide
www.thelancet.com/journals/lan... in @thelancet.com
(Yeah I know it’s #KidneyWk but what do we do till Houston wakes up!)
cc @rnflex.bsky.social
06.11.2025 13:54 — 👍 10 🔁 4 💬 1 📌 0
low dose Tac + Everolimus is not superior to Tac + MMF in older transplant recipients
in @asnpublications.bsky.social
another LBCT from #KidneyWk published
journals.lww.com/jasn/fulltex...
07.11.2025 18:53 — 👍 5 🔁 1 💬 0 📌 0
Visual abstract
Sad story reflecting that most people start with HD and most of them die
Natural history of RRT from the ERA registry
The visual abstract in this case tells a lot
academic.oup.com/ndt/advance-...
@ndt-era.bsky.social #NephSky
04.11.2025 01:39 — 👍 9 🔁 2 💬 2 📌 0
>50% hd to death 😥
04.11.2025 07:13 — 👍 1 🔁 0 💬 0 📌 0
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
As expected, Iptacopan phase 3 in IgA nephropathy slows GFR decline
APPLAUSE-IgA
Adding another new medication we won’t be able to access or afford to our IgA armamentarium
#NephSky
www.novartis.com/news/media-r...
16.10.2025 11:28 — 👍 21 🔁 7 💬 3 📌 0
congrats to the poster price 🥳
16.10.2025 20:32 — 👍 1 🔁 0 💬 0 📌 0
viruses 🦠 can be superheroes 🦸♀️
Felix Herkner present
the statistical analysis plan
of the TTVguideIT trial
at the Austrian Transplant Congress
Torque Teni Virus guided immunosuppression #TTVguide
16.10.2025 18:47 — 👍 2 🔁 0 💬 1 📌 0
ah grad auf pubmed gefunden… und sie plant eine randomisiert kontrollierte studie zum thema apherese… find ich super… genau so eine studie fehlt
11.10.2025 09:09 — 👍 0 🔁 0 💬 0 📌 0
und wieso reicht sie nicht einfach einen antrag ein zur finanzierung ihrer wissenschaft bei drittmittelgebern, so wie alle anderen das machen, die auch forschung in der medizin machen und 0 oeffentlich gelder bekommen?
11.10.2025 09:03 — 👍 0 🔁 0 💬 0 📌 0
wo ist die studie zur „autoantikoerper entfernung“ publiziert?
11.10.2025 08:58 — 👍 0 🔁 0 💬 1 📌 0
University of Washington Division of Nephrology, Department of Medicine
BlueSky account of the Renal Pathology Society (RPS) #renalpath
https://www.renalpathsoc.org/
Official Bluesky Account of the Section of Nephrology at Yale Internal Medicine
https://medicine.yale.edu/internal-medicine/nephrol/
🩺 Academic Nephrologist, Ochsner Health, New Orleans, LA, USA
🎓Professor of Medicine, Ochsner Clinical School - The University of Queensland, QLD, Australia
🔬Self-proclaimed Pisse Prophet
Professor for Translational Nephrology, love Research and Nephrology
Horizon Europe-funded consortium that aims to improve Rheumatoid Arthritis care through precision medicine, patient-centered approaches, and optimizing existing treatments.
Kidney ❤️, MedEd , CKM 🫀🫘🍩stewardship, mom & 🍷 enthusiast
Stay tuned about Research, Science and Education by one of the longest-established medical education and research facilities in Europe. #MedUniWien
Junior doctor and researcher currently focused on kidney transplants @ChariteBerlin
Renewed Kidney Enthusiast
no longer in📍 Gary, Indiana
Girls Dad; Medical Intensivist @ Medical University of Vienna; #ARDS, #ECMO, #ECLS, #Cancer, #Immunosuppression; #EuroELSO Sci Com; #ELSO Registry SOC; Hyrox.
Rheumatologist, Medical University Vienna - Past-President of EULAR
Physician scientist from LMU Munich trying to understand how to maximise kidney lifespan for patients with kidney diseases
Virologist, MD | Viruses,Vaccines & Immunity
Professor of Virus Immunology, Medical University of Vienna | Opinions mine
Virology lab studying various aspects of entry glycoproteins of the human cytomegalovirus, part of the Center for Virology at the Medical University Vienna
www.youtube.com/@MarkusAtHome
